{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:36:45Z","timestamp":1790743005450,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","award":["PHRC interr\u00e9gional"],"award-info":[{"award-number":["PHRC interr\u00e9gional"]}],"id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020090","name":"Fondation Neurodis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Impulse control disorders (ICDs) are frequently encountered in Parkinson\u2019s disease (PD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>We aimed to assess whether clonidine, an \u03b12-adrenergic receptor agonist, would improve ICDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a multicentre trial in five movement disorder departments. Patients with PD and ICDs (<jats:italic>n<\/jats:italic>\u2009=\u200941) were enrolled in an 8-week, randomised (1:1), double-blind, placebo-controlled study of clonidine (75\u00a0\u03bcg twice a day). Randomisation and allocation to the trial group were carried out by a central computer system. The primary outcome was the change at 8\u00a0weeks in symptom severity using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease\u2013Rating Scale (QUIP-RS) score. A reduction of the most elevated subscore of the QUIP-RS of more than 3 points without any increase in the other QUIP-RS dimension defined success.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 15 May 2019 and 10 September 2021, 19 patients in the clonidine group and 20 patients in the placebo group were enrolled. The proportion difference of success in reducing QUIP-RS at 8\u00a0weeks, was 7% (one-sided upper 90% CI 27%) with 42.1% of success in the clonidine group and 35.0% in the placebo group. Compared to patients in the placebo group, patients in the clonidine group experienced a greater reduction in the total QUIP-RS score at 8\u00a0weeks (11.0 points vs. 3.6).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Clonidine was well tolerated but our study was not enough powerful to demonstrate significant superiority compared to placebo in reducing ICDs despite a greater reduction of total QUIP score at 8\u00a0weeks. A phase 3 study should be conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>The study was registered (NCT03552068) on clinicaltrials.gov on June 11, 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11814-y","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T14:02:52Z","timestamp":1687269772000},"page":"4851-4859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson\u2019s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial"],"prefix":"10.1007","volume":"270","clinical-trial-number":[{"clinical-trial-number":"nct03552068","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1516-5401","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Laurencin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Timestit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domitille Dilly","family":"Duchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Giordana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Meoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Huddlestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodor","family":"Danaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Anheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Fatisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikail","family":"Nourredine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Boulinguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Dhelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Ballanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Prange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Thobois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"issue":"3","key":"11814_CR1","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"JC Corvol","year":"2018","unstructured":"Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91(3):e189-201","journal-title":"Neurology"},{"issue":"2","key":"11814_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/mds.26099","volume":"30","author":"M Samuel","year":"2015","unstructured":"Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie J, Ray Chaudhuri K, Brown R et al (2015) Impulse control disorders in Parkinson\u2019s disease:management, controversies, and potential approaches. Mov Disord Off J Mov Disord Soc 30(2):150\u2013159","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"11814_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson\u2019s disease. Int Rev Neurobiol 133:679\u2013717","journal-title":"Int Rev Neurobiol"},{"issue":"12","key":"11814_CR4","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1002\/mds.28745","volume":"36","author":"M Onofrj","year":"2021","unstructured":"Onofrj M, Di Iorio A, Carrarini C, Russo M, Franciotti R, Espay AJ et al (2021) Preexisting bipolar disorder influences the subsequent phenotype of Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 36(12):2840\u20132852","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"7","key":"11814_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/acn3.51569","volume":"9","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Posavi M, Fontanillas P, Tropea TF, Mamikonyan E, Suh E et al (2022) Genetic prediction of impulse control disorders in Parkinson\u2019s disease. Ann Clin Transl Neurol 9(7):936\u2013949","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"11814_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ene.12646","volume":"22","author":"H Baumann-Vogel","year":"2015","unstructured":"Baumann-Vogel H, Valko PO, Eisele G, Baumann CR (2015) Impulse control disorders in Parkinson\u2019s disease: don\u2019t set your mind at rest by self-assessments. Eur J Neurol 22(4):603\u2013609","journal-title":"Eur J Neurol"},{"issue":"12","key":"11814_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0269881114548437","volume":"28","author":"A Djamshidian","year":"2014","unstructured":"Djamshidian A, O\u2019Sullivan SS, Lawrence AD, Foltynie T, Aviles-Olmos I, Magdalinou N et al (2014) Perceptual decision-making in patients with Parkinson\u2019s disease. J Psychopharmacol Oxf Engl 28(12):1149\u20131154","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"1","key":"11814_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","volume":"67","author":"CA Rabinak","year":"2010","unstructured":"Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67(1):58\u201363","journal-title":"Arch Neurol"},{"issue":"5","key":"11814_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/mds.26160","volume":"30","author":"C Siri","year":"2015","unstructured":"Siri C, Cilia R, Reali E, Pozzi B, Cereda E, Colombo A et al (2015) Long-term cognitive follow-up of Parkinson\u2019s disease patients with impulse control disorders. Mov Disord 30(5):696\u2013704","journal-title":"Mov Disord"},{"key":"11814_CR10","doi-asserted-by":"crossref","unstructured":"Aracil-Bola\u00f1os I, Strafella AP (2016) Molecular imaging and neural networks in impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord 22 Suppl 1(Suppl 1):S101\u2013105","DOI":"10.1016\/j.parkreldis.2015.08.003"},{"issue":"3","key":"11814_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.22029","volume":"68","author":"A Thomas","year":"2010","unstructured":"Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400\u2013404","journal-title":"Ann Neurol"},{"issue":"6","key":"11814_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.22164","volume":"68","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V et al (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963\u2013968","journal-title":"Ann Neurol"},{"issue":"9","key":"11814_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","volume":"83","author":"K Papay","year":"2014","unstructured":"Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE et al (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83(9):826\u2013833","journal-title":"Neurology"},{"key":"11814_CR14","doi-asserted-by":"publisher","first-page":"6031478","DOI":"10.1155\/2017\/6031478","volume":"2017","author":"O Borodovitsyna","year":"2017","unstructured":"Borodovitsyna O, Flamini M, Chandler D (2017) Noradrenergic modulation of cognition in health and disease. Neural Plast 2017:6031478","journal-title":"Neural Plast"},{"issue":"Pt 6","key":"11814_CR15","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain J Neurol 128(Pt 6):1314\u20131322","journal-title":"Brain J Neurol"},{"issue":"14","key":"11814_CR16","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.26048","volume":"29","author":"AJ Espay","year":"2014","unstructured":"Espay AJ, LeWitt PA, Kaufmann H (2014) Norepinephrine deficiency in Parkinson\u2019s disease: the case for noradrenergic enhancement. Mov Disord Off J Mov Disord Soc 29(14):1710\u20131719","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"1","key":"11814_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s13311-012-0166-1","volume":"10","author":"E Favre","year":"2013","unstructured":"Favre E, Ballanger B, Thobois S, Broussolle E, Boulinguez P (2013) Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson\u2019s disease. Neurotherapeutics 10(1):154\u2013167","journal-title":"Neurotherapeutics"},{"issue":"17","key":"11814_CR18","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3390\/cells11172640","volume":"11","author":"M Criaud","year":"2022","unstructured":"Criaud M, Laurencin C, Poisson A, Metereau E, Redout\u00e9 J, Thobois S et al (2022) Noradrenaline and movement initiation disorders in Parkinson\u2019s disease: a pharmacological functional MRI Study with clonidine. Cells 11(17):2640","journal-title":"Cells"},{"issue":"5","key":"11814_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0893-133X(99)00060-3","volume":"21","author":"JS Franowicz","year":"1999","unstructured":"Franowicz JS, Arnsten AFT (1999) Treatment with the Noradrenergic Alpha-2 Agonist Clonidine, but not Diazepam, improves spatial working memory in normal young Rhesus Monkeys. Neuropsychopharmacology 21(5):611\u2013621","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"11814_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1440-1819.2003.01207.x","volume":"58","author":"S Miyazaki","year":"2004","unstructured":"Miyazaki S, Uchida S, Mukai J, Nishihara K (2004) Clonidine effects on all-night human sleep: opposite action of low- and medium-dose clonidine on human NREM\u2013REM sleep proportion. Psychiatry Clin Neurosci 58(2):138\u2013144","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"11814_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.pbb.2011.01.020","volume":"99","author":"AFT Arnsten","year":"2011","unstructured":"Arnsten AFT, Pliszka SR (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit\/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 99(2):211\u2013216","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"11814_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1124\/mol.113.090118","volume":"85","author":"KT Schmidt","year":"2014","unstructured":"Schmidt KT, Weinshenker D (2014) Adrenaline rush: The role of adrenergic receptors in stimulant-induced behaviors. Mol Pharmacol 85(4):640\u2013650","journal-title":"Mol Pharmacol"},{"issue":"Pt 7","key":"11814_CR23","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/brain\/awu117","volume":"137","author":"AA Kehagia","year":"2014","unstructured":"Kehagia AA, Housden CR, Regenthal R, Barker RA, M\u00fcller U, Rowe J et al (2014) Targeting impulsivity in Parkinson\u2019s disease using atomoxetine. Brain J Neurol 137(Pt 7):1986\u20131997","journal-title":"Brain J Neurol"},{"issue":"1","key":"11814_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029084","volume":"7","author":"XL Zhang","year":"2012","unstructured":"Zhang XL, Wang GB, Zhao LY, Sun LL, Wang J, Wu P et al (2012) Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts. PLoS ONE 7(1):e29084","journal-title":"PLoS ONE"},{"issue":"6","key":"11814_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/WNF.0b013e3182741c39","volume":"35","author":"AE Cavanna","year":"2012","unstructured":"Cavanna AE, Selvini C, Termine C, Balottin U, Eddy CM (2012) Tolerability profile of clonidine in the treatment of adults with Tourette syndrome. Clin Neuropharmacol 35(6):269\u2013272","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"11814_CR26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Stewart S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease (QUIP). Mov Disord Off J Mov Disord Soc 24(10):1461\u20131467","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"11814_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561\u2013571","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"11814_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","volume":"165","author":"C Ardouin","year":"2009","unstructured":"Ardouin C, Ch\u00e9reau I, Llorca PM, Lhomm\u00e9e E, Durif F, Pollak P et al (2009) Assessment of hyper- and hypodopaminergic behaviors in Parkinson\u2019s disease. Rev Neurol (Paris) 165(11):845\u2013856","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"11814_CR29","first-page":"270","volume":"28","author":"F Mondolo","year":"2007","unstructured":"Mondolo F, Jahanshahi M, Gran\u00e0 A, Biasutti E, Cacciatori E, Di Benedetto P (2007) Evaluation of anxiety in Parkinson\u2019s disease with some commonly used rating scales. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 28(5):270\u2013275","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"4","key":"11814_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1008979705027","volume":"8","author":"DM Bushnell","year":"1999","unstructured":"Bushnell DM, Martin ML (1999) Quality of life and Parkinson\u2019s disease: translation and validation of the US Parkinson\u2019s disease Questionnaire (PDQ-39). Qual Life Res Int J Qual Life Asp Treat Care Rehabil 8(4):345\u2013350","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"15","key":"11814_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord Off J Mov Disord Soc 23(15):2129\u20132170","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"6","key":"11814_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540\u2013545","journal-title":"Sleep"},{"issue":"2","key":"11814_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jclinepi.2012.09.002","volume":"66","author":"K Cocks","year":"2013","unstructured":"Cocks K, Torgerson DJ (2013) Sample size calculations for pilot randomized trials: a confidence interval approach. J Clin Epidemiol 66(2):197\u2013201","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"11814_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41531-020-00142-x","volume":"6","author":"A Castrioto","year":"2020","unstructured":"Castrioto A, Thobois S, Anheim M, Quesada JL, Lhomm\u00e9e E, Klinger H et al (2020) A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD. NPJ Park Dis 6(1):41","journal-title":"NPJ Park Dis"},{"issue":"5","key":"11814_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/mds.26108","volume":"30","author":"D Okai","year":"2015","unstructured":"Okai D, Askey-Jones S, Samuel M, David AS, Brown RG (2015) Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson\u2019s disease. Mov Disord 30(5):736\u2013739","journal-title":"Mov Disord"},{"key":"11814_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102330","volume":"27","author":"BN Haagensen","year":"2020","unstructured":"Haagensen BN, Herz DM, Meder D, Madsen KH, L\u00f8kkegaard A, Siebner HR (2020) Linking brain activity during sequential gambling to impulse control in Parkinson\u2019s disease. NeuroImage Clin 27:102330","journal-title":"NeuroImage Clin"},{"issue":"Pt 8","key":"11814_CR37","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1093\/brain\/aww138","volume":"139","author":"CL Rae","year":"2016","unstructured":"Rae CL, Nombela C, Rodr\u00edguez PV, Ye Z, Hughes LE, Jones PS et al (2016) Atomoxetine restores the response inhibition network in Parkinson\u2019s disease. Brain J Neurol 139(Pt 8):2235\u20132248","journal-title":"Brain J Neurol"},{"issue":"5","key":"11814_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010079","volume":"18","author":"FH Hezemans","year":"2022","unstructured":"Hezemans FH, Wolpe N, O\u2019Callaghan C, Ye R, Rua C, Jones PS et al (2022) Noradrenergic deficits contribute to apathy in Parkinson\u2019s disease through the precision of expected outcomes. PLoS Comput Biol 18(5):e1010079","journal-title":"PLoS Comput Biol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11814-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11814-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11814-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T04:03:53Z","timestamp":1695182633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11814-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["11814"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11814-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}